Literature DB >> 27733572

Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.

Helen L Wright1, Trevor Cox2, Robert J Moots3, Steven W Edwards4.   

Abstract

Neutrophils are implicated in the pathology of rheumatoid arthritis (RA), but the mechanisms regulating their activation are largely unknown. RA is a heterogeneous disease, and whereas many patients show clinical improvement during TNF inhibitor (TNFi) therapy, a significant proportion fails to respond. In vitro activation of neutrophils with agents, including TNF, results in rapid and selective changes in gene expression, but how neutrophils contribute to TNF signaling in RA and whether TNFi sensitivity involves differential neutrophil responses are unknown. With the use of RNA sequencing (RNA-Seq), we analyzed blood neutrophils from 20 RA patients, pre-TNFi therapy, to identify biomarkers of response, measured by a decrease in disease activity score based on 28 joint count (DAS28), 12 wk post-therapy. Biomarkers were validated by quantitative PCR (qPCR) of blood neutrophils from 2 further independent cohorts of RA patients: 16 pre-TNFi and 16 predisease-modifying anti-rheumatic drugs (DMARDs). Twenty-three neutrophil transcripts predicted a 12-wk response to TNFi: 10 (IFN-regulated) genes predicting a European League against Rheumatism (EULAR) good response and 13 different genes [neutrophil granule protein (NGP) genes] predicting a nonresponse. Statistical analysis indicated a predictive sensitivity and specificity of each gene in the panel of >80%, with some 100% specific. A combination of 3 genes [cytidine monophosphate kinase 2 (CMPK2), IFN-induced protein with tetratricopeptide repeats 1B (IFIT1B), and RNASE3] had the greatest predictive power [area under the curve (AUC) 0.94]. No correlation was found for a response to DMARDs. We conclude that this panel of genes is selective for predicting a response to TNFi and is not a surrogate marker for disease improvement. We also show that in RA, there is great plasticity in neutrophil phenotype, with circulating cells expressing genes normally only expressed in more immature cells. © Society for Leukocyte Biology.

Entities:  

Keywords:  RNA-Seq; TNFi; biomarker; transcriptome

Mesh:

Substances:

Year:  2016        PMID: 27733572     DOI: 10.1189/jlb.5A0616-258R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.

Authors:  Takeshi Iwasaki; Ryu Watanabe; Hiromu Ito; Takayuki Fujii; Kenji Okuma; Takuma Oku; Yoshitaka Hirayama; Koichiro Ohmura; Koichi Murata; Kosaku Murakami; Hiroyuki Yoshitomi; Masao Tanaka; Shuichi Matsuda; Fumihiko Matsuda; Akio Morinobu; Motomu Hashimoto
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

2.  Blood neutrophil count and neutrophil-to-lymphocyte ratio predict disease progression and mortality in two independent systemic sclerosis cohorts.

Authors:  Nancy Wareing; Vishnu Mohan; Rana Taherian; Elizabeth R Volkmann; Marka A Lyons; Holly Wilhalme; Michael D Roth; Rosa M Estrada-Y-Martin; Brian Skaug; Maureen D Mayes; Donald P Tashkin; Shervin Assassi
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-03-14       Impact factor: 5.178

Review 3.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 4.  Potential clinical biomarkers in rheumatoid arthritis with an omic approach.

Authors:  Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda
Journal:  Auto Immun Highlights       Date:  2021-05-31

5.  Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Authors:  Elinor A Chapman; Max Lyon; Deborah Simpson; David Mason; Robert J Beynon; Robert J Moots; Helen L Wright
Journal:  Front Immunol       Date:  2019-03-11       Impact factor: 7.561

6.  A robust intracellular metabolite extraction protocol for human neutrophil metabolic profiling.

Authors:  Susama Chokesuwattanaskul; Marie M Phelan; Steven W Edwards; Helen L Wright
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

7.  Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.

Authors:  Nida Meednu; Jennifer Barnard; Kelly Callahan; Andreea Coca; Bethany Marston; Ralf Thiele; Darren Tabechian; Marcy Bolster; Jeffrey Curtis; Meggan Mackay; Jonathan Graf; Richard Keating; Edwin Smith; Karen Boyle; Lynette Keyes-Elstein; Beverly Welch; Ellen Goldmuntz; Jennifer H Anolik
Journal:  Arthritis Rheumatol       Date:  2021-12-27       Impact factor: 15.483

8.  Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.

Authors:  Xiang Guo; Shiliang Wang; Alex Godwood; David Close; Patricia C Ryan; Lorin K Roskos; Wendy I White
Journal:  Int J Rheum Dis       Date:  2018-10-24       Impact factor: 2.454

9.  IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.

Authors:  Javier Rodríguez-Carrio; Patricia López; Mercedes Alperi-López; Luis Caminal-Montero; Francisco J Ballina-García; Ana Suárez
Journal:  Front Immunol       Date:  2019-01-07       Impact factor: 7.561

10.  Increased expression of CXCL2 in ACPA-positive rheumatoid arthritis and its role in osteoclastogenesis.

Authors:  X Wang; L Sun; N He; Z An; R Yu; C Li; Y Li; Y Li; X Liu; X Fang; J Zhao
Journal:  Clin Exp Immunol       Date:  2020-10-21       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.